POS1607 BIOLOGICS THERAPIES FOR PSORIASIS DECREASE FUTURE RISK FOR DEVELOPING PSORIATIC ARTHRITIS
BackgroundPsoriasis (PsO) is an inflammatory skin disorder with an estimated worldwide prevalence of 2–4% [1]. Psoriatic arthritis (PsA) is highly associated with higher severity of PsO, present in up to 30% of patients and 0.3–1.0% of the global population and PsA typically develops after PsO [1,2]...
Uložené v:
| Vydané v: | Annals of the rheumatic diseases Ročník 82; číslo Suppl 1; s. 1148 - 1149 |
|---|---|
| Hlavní autori: | , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Kidlington
BMJ Publishing Group Ltd and European League Against Rheumatism
01.06.2023
Elsevier B.V Elsevier Limited |
| Predmet: | |
| ISSN: | 0003-4967, 1468-2060 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | BackgroundPsoriasis (PsO) is an inflammatory skin disorder with an estimated worldwide prevalence of 2–4% [1]. Psoriatic arthritis (PsA) is highly associated with higher severity of PsO, present in up to 30% of patients and 0.3–1.0% of the global population and PsA typically develops after PsO [1,2]. There are some contradictory studies in relationship to the impact of biological therapies for PsO in relationship to the prevention of PsA.ObjectivesTo ascertain whether biological therapies for pre-existing psoriasis (PsO) may reduce the incidence of psoriatic arthritis (PsA) according to different treatment regimens for PsO ranging from topical therapy to biological therapy.MethodsWe conducted a retrospective exploratory study with real-world data from the third largest Israeli health maintenance organization, ‘Meuhedet’ which covers approximately 1,300,000 subjects. All patients of ‘Muehedat’ diagnosed with PsO from January 2000 until January 2020 were included in the analysis. Overall, 61,003 patients with PsO were detected. In addition, each PsO patient was paired with four control subjects by gender, age, and ethnicity. Patients diagnosed with PsA before the diagnosis of PsO or less than six months after were excluded from the analysis. We defined PsO according to physicians’ diagnoses. PsA included patients with either peripheral or axial arthritis.Patients were classified according to their treatment; Group 1-topical therapy, phototherapy or no therapy, Group 2 - conventional DMARDs (cDMARDs; methotrexate or sulfasalazine), Group 3 -biologics DMARDs (bDMARD) The incident cases of PsA were analyzed according to the aforementioned different lines of therapy. Patients in the bDMARDs group were further sub-grouped according to the first-line prescribed treatment. Time-dependent Cox proportional hazard models were used to evaluate the adjusted risk of developing PsA by treatment group. Data analysis was conducted with Python Software Foundation, Python Language Reference, version 3.9.12, R version 4.2.0, RStudio (RStudio Team, 2020), and the ‘Survival’ package (v3.2; Therneau, 2020).Results58,671 patients were included contributing a total of 628,228 patient-years. This analysis was adjusted to gender, body mass index (BMI), age of PsO diagnosis, time from psoriasis diagnosis to the group treatment, and number of biological treatments lines. Adjusted Cox proportional hazards regression analysis showed that the risk of developing PsA in PsO patients treated with cDMARDs was significantly higher in comparison to those treated with topical therapy (HR: 2.76, CI: 2.19 – 3.48, p-value: <0.001). On the contrary, the analysis also showed that the risk of developing PsA in PsO patients was significantly decreased in those treated with biological agents in comparison to topical therapy (HR: 0.62, CI: 0.42 – 0.90, p-value: <0.014).ConclusionPsO patients treated with cDMARDs are at higher risk of developing PsA in comparison to those treated with topical therapy alone which may reflect the severity of extent of psoriasis in the c DMARD group been linked to PsA. Biological therapy decreased risk of developing PsA in comparison to topical therapy.References[1]Mease PJ, Palmer JB, Hur P, Strober BE, Lebwohl M, Karki C, et al. Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry. Journal of the European Academy of Dermatology and Venereology 2019;33:886–92.[2]Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population-based study. Arthritis Care Res (Hoboken) 2009;61:233–9.[3]Koolaee RM, Takeshita J, Ogdie A. Epidemiology and Natural History of Psoriatic Arthritis: An Update What Dermatologists Need to Know. Curr Dermatol Rep 2013;2:66–76.Acknowledgements:NIL.Disclosure of InterestsNone Declared. |
|---|---|
| AbstractList | BackgroundPsoriasis (PsO) is an inflammatory skin disorder with an estimated worldwide prevalence of 2–4% [1]. Psoriatic arthritis (PsA) is highly associated with higher severity of PsO, present in up to 30% of patients and 0.3–1.0% of the global population and PsA typically develops after PsO [1,2]. There are some contradictory studies in relationship to the impact of biological therapies for PsO in relationship to the prevention of PsA.ObjectivesTo ascertain whether biological therapies for pre-existing psoriasis (PsO) may reduce the incidence of psoriatic arthritis (PsA) according to different treatment regimens for PsO ranging from topical therapy to biological therapy.MethodsWe conducted a retrospective exploratory study with real-world data from the third largest Israeli health maintenance organization, ‘Meuhedet’ which covers approximately 1,300,000 subjects. All patients of ‘Muehedat’ diagnosed with PsO from January 2000 until January 2020 were included in the analysis. Overall, 61,003 patients with PsO were detected. In addition, each PsO patient was paired with four control subjects by gender, age, and ethnicity. Patients diagnosed with PsA before the diagnosis of PsO or less than six months after were excluded from the analysis. We defined PsO according to physicians’ diagnoses. PsA included patients with either peripheral or axial arthritis.Patients were classified according to their treatment; Group 1-topical therapy, phototherapy or no therapy, Group 2 - conventional DMARDs (cDMARDs; methotrexate or sulfasalazine), Group 3 -biologics DMARDs (bDMARD) The incident cases of PsA were analyzed according to the aforementioned different lines of therapy. Patients in the bDMARDs group were further sub-grouped according to the first-line prescribed treatment. Time-dependent Cox proportional hazard models were used to evaluate the adjusted risk of developing PsA by treatment group. Data analysis was conducted with Python Software Foundation, Python Language Reference, version 3.9.12, R version 4.2.0, RStudio (RStudio Team, 2020), and the ‘Survival’ package (v3.2; Therneau, 2020).Results58,671 patients were included contributing a total of 628,228 patient-years. This analysis was adjusted to gender, body mass index (BMI), age of PsO diagnosis, time from psoriasis diagnosis to the group treatment, and number of biological treatments lines. Adjusted Cox proportional hazards regression analysis showed that the risk of developing PsA in PsO patients treated with cDMARDs was significantly higher in comparison to those treated with topical therapy (HR: 2.76, CI: 2.19 – 3.48, p-value: <0.001). On the contrary, the analysis also showed that the risk of developing PsA in PsO patients was significantly decreased in those treated with biological agents in comparison to topical therapy (HR: 0.62, CI: 0.42 – 0.90, p-value: <0.014).ConclusionPsO patients treated with cDMARDs are at higher risk of developing PsA in comparison to those treated with topical therapy alone which may reflect the severity of extent of psoriasis in the c DMARD group been linked to PsA. Biological therapy decreased risk of developing PsA in comparison to topical therapy.References[1]Mease PJ, Palmer JB, Hur P, Strober BE, Lebwohl M, Karki C, et al. Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry. Journal of the European Academy of Dermatology and Venereology 2019;33:886–92.[2]Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population-based study. Arthritis Care Res (Hoboken) 2009;61:233–9.[3]Koolaee RM, Takeshita J, Ogdie A. Epidemiology and Natural History of Psoriatic Arthritis: An Update What Dermatologists Need to Know. Curr Dermatol Rep 2013;2:66–76.Acknowledgements:NIL.Disclosure of InterestsNone Declared. Psoriasis (PsO) is an inflammatory skin disorder with an estimated worldwide prevalence of 2–4% [1]. Psoriatic arthritis (PsA) is highly associated with higher severity of PsO, present in up to 30% of patients and 0.3–1.0% of the global population and PsA typically develops after PsO [1,2]. There are some contradictory studies in relationship to the impact of biological therapies for PsO in relationship to the prevention of PsA. To ascertain whether biological therapies for pre-existing psoriasis (PsO) may reduce the incidence of psoriatic arthritis (PsA) according to different treatment regimens for PsO ranging from topical therapy to biological therapy. We conducted a retrospective exploratory study with real-world data from the third largest Israeli health maintenance organization, ‘Meuhedet’ which covers approximately 1,300,000 subjects. All patients of ‘Muehedat’ diagnosed with PsO from January 2000 until January 2020 were included in the analysis. Overall, 61,003 patients with PsO were detected. In addition, each PsO patient was paired with four control subjects by gender, age, and ethnicity. Patients diagnosed with PsA before the diagnosis of PsO or less than six months after were excluded from the analysis. We defined PsO according to physicians' diagnoses. PsA included patients with either peripheral or axial arthritis. Patients were classified according to their treatment; Group 1-topical therapy, phototherapy or no therapy, Group 2 - conventional DMARDs (cDMARDs; methotrexate or sulfasalazine), Group 3 -biologics DMARDs (bDMARD) The incident cases of PsA were analyzed according to the aforementioned different lines of therapy. Patients in the bDMARDs group were further sub-grouped according to the first-line prescribed treatment. Time-dependent Cox proportional hazard models were used to evaluate the adjusted risk of developing PsA by treatment group. Data analysis was conducted with Python Software Foundation, Python Language Reference, version 3.9.12, R version 4.2.0, RStudio (RStudio Team, 2020), and the ‘Survival’ package (v3.2; Therneau, 2020). 58,671 patients were included contributing a total of 628,228 patient-years. This analysis was adjusted to gender, body mass index (BMI), age of PsO diagnosis, time from psoriasis diagnosis to the group treatment, and number of biological treatments lines. Adjusted Cox proportional hazards regression analysis showed that the risk of developing PsA in PsO patients treated with cDMARDs was significantly higher in comparison to those treated with topical therapy (HR: 2.76, CI: 2.19 – 3.48, p-value: <0.001). On the contrary, the analysis also showed that the risk of developing PsA in PsO patients was significantly decreased in those treated with biological agents in comparison to topical therapy (HR: 0.62, CI: 0.42 – 0.90, p-value: <0.014). PsO patients treated with cDMARDs are at higher risk of developing PsA in comparison to those treated with topical therapy alone which may reflect the severity of extent of psoriasis in the c DMARD group been linked to PsA. Biological therapy decreased risk of developing PsA in comparison to topical therapy. [1]Mease PJ, Palmer JB, Hur P, Strober BE, Lebwohl M, Karki C, et al. Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry. Journal of the European Academy of Dermatology and Venereology 2019;33:886–92. [2]Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population-based study. Arthritis Care Res (Hoboken) 2009;61:233–9. [3]Koolaee RM, Takeshita J, Ogdie A. Epidemiology and Natural History of Psoriatic Arthritis: An Update What Dermatologists Need to Know. Curr Dermatol Rep 2013;2:66–76. NIL. None Declared. |
| Author | Ben-Shabat, N. Dotan, A. Watad, A. Mcgonagle, D. Amital, H. |
| Author_xml | – sequence: 1 givenname: A. surname: Dotan fullname: Dotan, A. organization: Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel, Sackler Faculty of Medicine, Tel-Aviv University, Department of Medicine ‘B’, Ramat-Gan, Israel – sequence: 2 givenname: N. surname: Ben-Shabat fullname: Ben-Shabat, N. organization: Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel, Sackler Faculty of Medicine, Tel-Aviv University, Department of Medicine ‘B’, Ramat-Gan, Israel – sequence: 3 givenname: D. surname: Mcgonagle fullname: Mcgonagle, D. organization: The Leeds Teaching Hospitals NHS Trust & Leeds Institute of, University of Leeds, Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom – sequence: 4 givenname: H. surname: Amital fullname: Amital, H. organization: Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel, Sackler Faculty of Medicine, Tel-Aviv University, Department of Medicine ‘B’, Ramat-Gan, Israel – sequence: 5 givenname: A. surname: Watad fullname: Watad, A. organization: Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel, Sackler Faculty of Medicine, Tel-Aviv University, Department of Medicine ‘B’, Ramat-Gan, Israel |
| BookMark | eNqNkE9PwjAYhxujiYB-hyWch23XtVs8TSjQSBxZh9emG10cgQ07MPHmxS_qJ3H8SfTIqWnz_H5v36cLrqu6MgD0ERwg5NEHXVX2zew3y7JxMcSea_ZrbQfE9-kV6CBCg_aZwmvQgRB6LgkpuwXdplm1VxigoAPyeSwRhezn6_tJxLN4IobSSac8ieaCS2ccJ85cxomIpJDOiA8THknujBfpIuFOIuTzERnxVz6L5-JlcqZTMXSiJJ0mIhXyDtwUet2Y-_PZA4sxT4dT9zgumrkZJh51M0IMLkJCNM0z7RcYQ619zVCmGWaQeQFBXgE1pSEK291MmNGALgtGQwYh1l4P9E-9W1u_702zU6t6b6t2pMIB9j3kt2BLPZ6o3NZNY02htrbcaPupEFQHq-qfVXWwqo5W1cFqm-antGkX-SiNVU1emio3y9KafKeWdXlhDzv1ZJvV3zcvSf4CpmqVqw |
| ContentType | Journal Article |
| Copyright | Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. 2023 © Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by Elsevier Inc. 2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. |
| Copyright_xml | – notice: Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2023 © Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by Elsevier Inc. – notice: 2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. |
| DBID | AAYXX CITATION K9. |
| DOI | 10.1136/annrheumdis-2023-eular.4556 |
| DatabaseName | CrossRef ProQuest Health & Medical Complete (Alumni) |
| DatabaseTitle | CrossRef ProQuest Health & Medical Complete (Alumni) |
| DatabaseTitleList | ProQuest Health & Medical Complete (Alumni) |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1468-2060 |
| EndPage | 1149 |
| ExternalDocumentID | 10_1136_annrheumdis_2023_eular_4556 S0003496724649927 annrheumdis |
| GroupedDBID | --- .55 .GJ .VT 169 23M 2WC 39C 3O- 4.4 40O 53G 5GY 5RE 5VS 6J9 7X7 7~S 88E 88I 8AF 8FE 8FH 8FI 8FJ 8R4 8R5 AAHLL AAKAS AAOJX AAWJN AAWTL AAXUO ABAAH ABJNI ABKDF ABMQD ABOCM ABTFR ABUWG ABVAJ ACGFO ACGFS ACGOD ACGTL ACHTP ACMFJ ACOAB ACOFX ACPRK ACQSR ACTZY ADBBV ADCEG ADFRT ADUGQ ADZCM AEKJL AENEX AFKRA AFWFF AGQPQ AHMBA AHNKE AHQMW AJYBZ AKKEP ALIPV ALMA_UNASSIGNED_HOLDINGS ASPBG AVWKF AZFZN AZQEC BAWUL BBNVY BENPR BHPHI BKNYI BLJBA BOMFT BPHCQ BTFSW BTHHO BVXVI C1A C45 CAG CCPQU COF CS3 CXRWF DIK DWQXO E3Z EBS EJD F5P FDB FYUFA GNUQQ H13 HAJ HCIFZ HMCUK HYE HZ~ IAO IEA IHR INH INR IOF ITC J5H K9- KQ8 L7B LK8 M0R M1P M2P M7P N9A NTWIH NXWIF O9- OK1 OVD P2P PHGZT PQQKQ PROAC PSQYO Q2X R53 RHI RMJ RPM RV8 RWL RXW TAE TEORI TR2 UAW UKHRP UYXKK V24 VM9 VVN W2D W8F WH7 WOQ X6Y X7M YFH YOC YQY ZGI ZXP 0R~ AALRI AAFWJ AAYXX AFFHD CITATION PHGZM PJZUB PPXIY PQGLB K9. |
| ID | FETCH-LOGICAL-b2436-b44e2f944a6cba5f220aa5a71ba7270738413f0a66919146e9b686df7697002a3 |
| ISSN | 0003-4967 |
| IngestDate | Tue Oct 07 07:43:15 EDT 2025 Sat Nov 29 08:08:35 EST 2025 Sat Mar 15 15:43:59 EDT 2025 Thu Apr 24 22:49:57 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | Suppl 1 |
| Keywords | Disease-modifying drugs (DMARDs) bDMARD Psoriatic arthritis |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-b2436-b44e2f944a6cba5f220aa5a71ba7270738413f0a66919146e9b686df7697002a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
| OpenAccessLink | https://ard.bmj.com/content/annrheumdis/82/Suppl_1/1148.full.pdf |
| PQID | 2825315970 |
| PQPubID | 2041045 |
| PageCount | 2 |
| ParticipantIDs | proquest_journals_2825315970 crossref_primary_10_1136_annrheumdis_2023_eular_4556 elsevier_sciencedirect_doi_10_1136_annrheumdis_2023_eular_4556 bmj_journals_10_1136_annrheumdis_2023_eular_4556 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-June June 2023 2023-06-00 20230601 |
| PublicationDateYYYYMMDD | 2023-06-01 |
| PublicationDate_xml | – month: 06 year: 2023 text: 2023-June |
| PublicationDecade | 2020 |
| PublicationPlace | Kidlington |
| PublicationPlace_xml | – name: Kidlington |
| PublicationTitle | Annals of the rheumatic diseases |
| PublicationTitleAbbrev | Ann Rheum Dis |
| PublicationYear | 2023 |
| Publisher | BMJ Publishing Group Ltd and European League Against Rheumatism Elsevier B.V Elsevier Limited |
| Publisher_xml | – name: BMJ Publishing Group Ltd and European League Against Rheumatism – name: Elsevier B.V – name: Elsevier Limited |
| SSID | ssj0000818 |
| Score | 2.4187822 |
| Snippet | BackgroundPsoriasis (PsO) is an inflammatory skin disorder with an estimated worldwide prevalence of 2–4% [1]. Psoriatic arthritis (PsA) is highly associated... Psoriasis (PsO) is an inflammatory skin disorder with an estimated worldwide prevalence of 2–4% [1]. Psoriatic arthritis (PsA) is highly associated with higher... |
| SourceID | proquest crossref elsevier bmj |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 1148 |
| SubjectTerms | Antibiotics bDMARD Biological products Body mass index Diagnosis Disease-modifying drugs (DMARDs) Epidemiology Gender Health maintenance organizations HMOs HuR protein Immunotherapy Methotrexate Patients Phototherapy Population studies Psoriasis Psoriatic arthritis Scientific Abstracts Skin diseases Sulfasalazine |
| Title | POS1607 BIOLOGICS THERAPIES FOR PSORIASIS DECREASE FUTURE RISK FOR DEVELOPING PSORIATIC ARTHRITIS |
| URI | https://ard.bmj.com/content/82/Suppl_1/1148.full https://dx.doi.org/10.1136/annrheumdis-2023-eular.4556 https://www.proquest.com/docview/2825315970 |
| Volume | 82 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1468-2060 dateEnd: 20241231 omitProxy: false ssIdentifier: ssj0000818 issn: 0003-4967 databaseCode: M7P dateStart: 19390101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1468-2060 dateEnd: 20241231 omitProxy: false ssIdentifier: ssj0000818 issn: 0003-4967 databaseCode: M0R dateStart: 19390101 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1468-2060 dateEnd: 20241231 omitProxy: false ssIdentifier: ssj0000818 issn: 0003-4967 databaseCode: 7X7 dateStart: 19390101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1468-2060 dateEnd: 20241231 omitProxy: false ssIdentifier: ssj0000818 issn: 0003-4967 databaseCode: BENPR dateStart: 19390101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1468-2060 dateEnd: 20241231 omitProxy: false ssIdentifier: ssj0000818 issn: 0003-4967 databaseCode: M2P dateStart: 19390101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bT9swFLYKTGgv066CjVWWtrcqXZo4dvwyKUAR0UaJkjL1LXKCA5tGQFAQj3vZD9hf3C_Z8SVJxS7qNO3FbSzXSXw--1x6Lgi9BuD67nFFnLIKfYeAUuEIOIodRitgFnxUEV0b8MN7NpmEsxlPer1vTSzMzWdW1-HtLb_4r6SGPiC2Cp39C3K3k0IHfAeiQwtkh3YpwieHmUrnZr0YwmA7NgUPMuXdk0YJyH8DUP0GSXaYxlEWZ4Pd8U46jrLxYO9IO0GkcfZOD7EVOpVBy4yeAs1AAt5P42mcLcq1XR5m7bJ4Kq9NKlj7_09Xvf58biyu0bA1BMjayU5FIeYm8quzFJ6AlnBi3J132-7oTJU50RxzuGiy8PzOtcrY0X6KpbFnM4CFm-IczdlsChPZw1WpbguMGi75r5mAb7Mf67eFF3X0Q0jl1zskQXAn9bZm5pnJ1EOZRygogR5bQWseC7g6KA_ctGPu4ShsijCq4evolb3lmz_cEASX4uzT70SfO0KAlmymD9EDq5LgyEDpEerJ-jFaP7BOF09QaRH1_cvXFku4xRIGoOAWS7jBEjZYwgpLekiHJdxiCbdYeoqO9sbTnX3H1uZwCo_41CkIkV7FCRG0LERQeZ4rRCDYqBAgEQPfCGGTV66glKsMglTygob0uGKUM2DCwn-GVuvzWm4gXEgCSi2VBD5JAOpwADp8EYBwVYakKotN5MLi5XaLXeVabfV1KH2z3rla71yvd67WexORZqXzC5O1ZbmfvW2oklsB1AiWOUBruQm2Glp2z6uiw33QGpj7_F_nf4Hud_tpC63OL6_lS3SvvJl_vLrsoxU2Y320tj2eJGlf41a1XqJalvwA5gKuoA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=POS1607%E2%80%85BIOLOGICS+THERAPIES+FOR+PSORIASIS+DECREASE+FUTURE+RISK+FOR+DEVELOPING+PSORIATIC+ARTHRITIS&rft.jtitle=Annals+of+the+rheumatic+diseases&rft.au=Dotan%2C+A.&rft.au=Ben-Shabat%2C+N.&rft.au=Mcgonagle%2C+D.&rft.au=Amital%2C+H.&rft.date=2023-06-01&rft.pub=Elsevier+B.V&rft.issn=0003-4967&rft.volume=82&rft.spage=1148&rft.epage=1149&rft_id=info:doi/10.1136%2Fannrheumdis-2023-eular.4556&rft.externalDocID=S0003496724649927 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0003-4967&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0003-4967&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0003-4967&client=summon |